Bristol Myers Squibb Company $BMY Stock Holdings Trimmed by Marietta Investment Partners LLC

Marietta Investment Partners LLC lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 26.5% in the third quarter, HoldingsChannel reports. The fund owned 36,187 shares of the biopharmaceutical company’s stock after selling 13,054 shares during the period. Marietta Investment Partners LLC’s holdings in Bristol Myers Squibb were worth $1,632,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Crossmark Global Holdings Inc. lifted its holdings in Bristol Myers Squibb by 8.1% in the third quarter. Crossmark Global Holdings Inc. now owns 246,488 shares of the biopharmaceutical company’s stock worth $11,117,000 after purchasing an additional 18,462 shares during the period. Orion Porfolio Solutions LLC lifted its stake in shares of Bristol Myers Squibb by 7.4% in the 3rd quarter. Orion Porfolio Solutions LLC now owns 51,484 shares of the biopharmaceutical company’s stock worth $2,322,000 after acquiring an additional 3,528 shares during the period. Advisory Alpha LLC increased its stake in shares of Bristol Myers Squibb by 7.0% during the third quarter. Advisory Alpha LLC now owns 9,634 shares of the biopharmaceutical company’s stock valued at $441,000 after acquiring an additional 633 shares during the period. IFG Advisory LLC bought a new stake in Bristol Myers Squibb during the third quarter worth approximately $2,337,000. Finally, Dimensional Fund Advisors LP lifted its position in Bristol Myers Squibb by 11.5% in the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company’s stock worth $818,105,000 after purchasing an additional 1,873,618 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Top-line Phase 2 results for Reblozyl in alpha‑thalassemia came back positive (primary and key secondary endpoints met; safety consistent with prior data), which strengthens BMY’s late‑stage pipeline optionality and potential label expansion. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Positive Sentiment: Commercial momentum: Reblozyl has topped roughly $2.3B in annualized sales and company commentary plus an AI collaboration (Evinova) to speed trial execution underline both near‑term revenue support and improved R&D efficiency. These items support BMY’s top‑line outlook if label/drug expansion continues. Can Reblozyl Stabilize BMY’s Top Line Amid Legacy Drugs Decline? Bristol Myers Squibb Adds Reblozyl Data And AI To Pipeline Story
• Neutral Sentiment: Round‑up/earnings coverage: BMY appears in lists of Q4 “outperformers” for branded pharma on revenue strength, but underlying EPS dynamics were mixed—investors should read the details rather than rely on headlines. Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
• Neutral Sentiment: Industry context: Strength at peers (e.g., Merck’s Keytruda momentum) highlights competitive dynamics in oncology that influence investor expectations for BMY’s oncology franchises. Merck’s Keytruda Drives its 2025 Revenue Surge: What’s Ahead?
• Neutral Sentiment: Macro/sector themes such as nanomedicine and dividend‑income positioning appeared in recent coverage; these are background drivers but less directly tied to BMY’s immediate price move. Global Nanomedicine Market is Projected Cross
• Negative Sentiment: Market reaction and fundamentals: several news pieces note BMY’s intraday/close decline (broader selling). The core negative catalysts are the Q4 EPS miss (reported EPS below consensus) and FY‑2026 guidance that sits below some analyst forecasts — these credit‑and‑earnings concerns explain why the stock is down despite pipeline positives. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $60.69 on Friday. The company has a market cap of $123.59 billion, a P/E ratio of 17.59, a price-to-earnings-growth ratio of 0.18 and a beta of 0.26. The company’s fifty day moving average is $57.55 and its two-hundred day moving average is $50.91. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same period in the previous year, the firm posted $1.67 earnings per share. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Barclays initiated coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target for the company. HSBC reaffirmed a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $60.71.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.